Tag: form

Continues to advance the project and is working directly with the hyperscaler customer

Continues to advance the project and is working directly with the hyperscaler customer

PORTLAND, Ore., June 10, 2026 /PRNewswire/ -- The Dyrt, the app to get the best campsites, built by the largest RVing and camping community...

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

In-Q-Tel joins as strategic investor to support Harbinger's expansion into government and national security marketsHarbinger Praesidia, the company's new defense vertical, provides configurable unmanned...

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

The withdrawal does not reflect any change in the Company's business outlook, operating strategy, or confidence in the value of its assetsDALLAS, June 10,...

The dancewear market is witnessing steady adoption across dance academies, professional dance companies, fitness centers, educational institutions, performance arts organizations, and individual consumers due...

New body of vibrant, expressive paintings explores consciousness, intuition, and the power of feeling — featuring powerful works incorporating Bruce Lee's iconic philosophy; artist...

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.